Linsitinib

Search with Google Search with Bing

Information
Drug Name
Linsitinib
Description
Entry(CIViC)
4
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
Ewing sarcoma CDKN2A LOSS
( ENST00000579755.2 ) CDKN2A LOSS
( ENST00000579755.2 ) 		D Predictive Supports Sensitivity/Response Somatic 2 27286459 Detail
Ewing sarcoma CDKN2B LOSS
( ENST00000276925.7 ) CDKN2B LOSS
( ENST00000276925.7 ) 		D Predictive Supports Sensitivity/Response Somatic 2 27286459 Detail
prostate cancer IGF2 OVEREXPRESSION IGF2 OVEREXPRESSION D Predictive Supports N/A Somatic 3 25670080 Detail
prostate cancer IGF2 OVEREXPRESSION IGF2 OVEREXPRESSION D Predictive Supports Sensitivity/Response Somatic 3 25670080 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A patient-derived xenograft (PDX) from a patient w... CDKN2A CDKN2A LOSS
( ENST00000579755.2 ) CDKN2A LOSS
( ENST00000579755.2 ) 		Sensitivity true CIViC Evidence detail
A patient-derived xenograft (PDX) from a patient w... CDKN2B CDKN2B LOSS
( ENST00000276925.7 ) CDKN2B LOSS
( ENST00000276925.7 ) 		Sensitivity true CIViC Evidence detail
OSI-906, an IGF1R/INSR inhibitor, does not have a ... IGF2 IGF2 OVEREXPRESSION IGF2 OVEREXPRESSION N/A true CIViC Evidence detail
OSI-906, an IGF1R/INSR inhibitor, sensitizes cell ... IGF2 IGF2 OVEREXPRESSION IGF2 OVEREXPRESSION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT05276063 Active, not recruiting Phase 2/Phase 3 A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) July 1, 2022 September 2026
NCT01533181 Completed Phase 2 Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer February 2012 November 2014
NCT01533246 Completed Phase 2 Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer February 2012 November 2012
NCT01560260 Completed Phase 2 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors March 2012 October 2015
NCT02057380 Completed Phase 2 A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial April 16, 2014 December 21, 2016
NCT02546544 Completed Phase 2 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma March 2014 July 15, 2016
NCT06112340 Recruiting Phase 2/Phase 3 A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) October 11, 2023 June 2026
NCT01465815 Withdrawn Phase 1/Phase 2 Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) December 2011 September 2013